Fumitremorgin C

CHF 100.00
In stock
BVT-0189-C250250 µgCHF 100.00
BVT-0189-M0011 mgCHF 185.00
More Information
Product Details
Synonyms FTC; Tryptoquivaline
Product Type Chemical


MW 379.5
CAS 118974-02-0
Source/Host Chemicals Isolated from Aspergillus fumigatus.
Purity Chemicals ≥98% (HPLC)
Appearance White to light brown powder.
Solubility Soluble in DMSO, methanol, acetone, DMF or chloroform.
Identity Determined by 1H-NMR.
Declaration Manufactured by BioViotica.
Other Product Data

A concentration of 1mg/ml is recommended for stock solutions.

Smiles [H][C@@]12CCCN1C(=O)[C@]1([H])CC3=C(NC4=C3C=CC(OC)=C4)[C@H](C=C(C)C)N1C2=O
Shipping and Handling
Shipping AMBIENT
Short Term Storage +4°C
Long Term Storage +4°C
Handling Advice Protect from light when in solution.
Use/Stability Stable for at least 1 year after receipt when stored at +4°C.
After reconstitution protect from light at -20°C.
MSDS Download PDF
Product Specification Sheet
Datasheet Download PDF
  • Mycotoxin.
  • Cytotoxic.
  • Tremorgenic.
  • Potent and specific inhibitor of the breast cancer resistance protein (BCRP; ABCG2).
  • Reverses multidrug resistance mediated by BCRP and increases cytotoxicity of several anticancer agents in vitro.
Product References
  1. Mycotoxins produced by Aspergillus fumigatus species isolated from molded silage: R.J. Cole, et al.; J. Agric. Food Chem. 25, 826 (1977)
  2. Novel mammalian cell cycle inhibitors, tryprostatins A, B and other diketopiperazines produced by Aspergillus fumigatus. I. Taxonomy, fermentation, isolation and biological properties: C.B. Cui, et al.; J. Antibiot. 49, 527 (1996)
  3. Reversal of a novel multidrug resistance mechanism in human colon carcinoma cells by fumitremorgin: S.K. Rabindran, et al.; Cancer Res. 58, 5850 (1998)
  4. Fumitremorgin C reverses multidrug resistance in cells transfected with the breast cancer resistance protein.: S.K. Rabindran, et al.; Cancer Res. 60, 47 (2000)
  5. Characterization of drug transport, ATP hydrolysis, and nucleotide trapping by the human ABCG2 multidrug transporter. Modulation of substrate specificity by a point mutation.:Ozvegy, et al.; J. Biol. Chem. 277, 47980 (2002)
  6. The role of breast cancer resistance protein in acute lymphoblastic leukemia: S.L. Plasschaert, et al.; Clin. Cancer Res. 9, 5171 (2003)
  7. Plasma pharmacokinetics and tissue distribution of the breast cancer resistance protein (BCRP/ABCG2) inhibitor fumitremorgin C in SCID mice bearing T8 tumors: T.S. Garimella, et al.; Cancer Chemother. Pharmacol. 55, 101 (2005)
  8. Histone deacetylase inhibitors induce a very broad, pleiotropic anticancer drug resistance phenotype in acute myeloid leukemia cells by modulation of multiple ABC transporter genes: S. Hauswald, et al.; Clin. Cancer Res. 15, 3705 (2009)
  9. Specific inhibitors of the breast cancer resistance protein (BCRP): A. Pick, et al.; ChemMedChem 5, 1498 (2010)
  10. Differential inhibition of murine Bcrp1/Abcg2 and human BCRP/ABCG2 by the mycotoxin fumitremorgin C: L. Gonzales-Lobato, et al.; Eur. J. Pharmacol. 644, 41 (2010)
  11. Cytotoxic compounds from the marine-derived fungus Aspergillus sp. recovered from the sediments of the Brazilian coast: N. N. Saraiva, et al.; Nat. Prod. Res. 29, 1545 (2014)
  12. Cross-drug resistance to sunitinib induced by doxorubicin in endothelial cells: H.L. Huang, et al.; Oncol. Lett. 9, 1287 (2015)
  13. The oncogene-dependent resistance to reprogramming unveils cancer therapeutic targets: K. Ito, et al.; Cell Rep. 39, 110721 (2022)
© 2017 Adipogen Life Sciences. Pictures: © 2012 Martin Oeggerli. All Rights Reserved.